The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Leukemia, Myelocytic, Acute

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leukemia, Myelocytic, Acute


High impact information on Leukemia, Myelocytic, Acute


Chemical compound and disease context of Leukemia, Myelocytic, Acute


Biological context of Leukemia, Myelocytic, Acute


Anatomical context of Leukemia, Myelocytic, Acute


Gene context of Leukemia, Myelocytic, Acute


Analytical, diagnostic and therapeutic context of Leukemia, Myelocytic, Acute


  1. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Armstrong, S.A., Staunton, J.E., Silverman, L.B., Pieters, R., den Boer, M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R., Korsmeyer, S.J. Nat. Genet. (2002) [Pubmed]
  2. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., Kato, J., Hirayama, Y., Sakamaki, S., Kohda, K., Miyake, K., Niitsu, Y. Nat. Med. (2003) [Pubmed]
  3. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. Schwieger, M., Löhler, J., Friel, J., Scheller, M., Horak, I., Stocking, C. J. Exp. Med. (2002) [Pubmed]
  4. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. Liu, Q., Schwaller, J., Kutok, J., Cain, D., Aster, J.C., Williams, I.R., Gilliland, D.G. EMBO J. (2000) [Pubmed]
  5. Plasma and urine cyclic guanosine 3':5'-monophosphate in disseminated cancer. Chawla, R.K., Nixon, D.W., Shoji, M., Rudman, D. Ann. Intern. Med. (1979) [Pubmed]
  6. Ectopic ACTH production with autoantibody formation in a patient with acute myeloblastic leukemia. Pflüger, K.H., Gramse, M., Gropp, C., Havemann, K. N. Engl. J. Med. (1981) [Pubmed]
  7. The role of the c-mos gene in the 8;21 translocation in human acute myeloblastic leukemia. Diaz, M.O., Le Beau, M.M., Rowley, J.D., Drabkin, H.A., Patterson, D. Science (1985) [Pubmed]
  8. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Pelicci, P.G., Lanfrancone, L., Brathwaite, M.D., Wolman, S.R., Dalla-Favera, R. Science (1984) [Pubmed]
  9. Improved prospects for long-term survival in adults with acute myelogenous leukemia. Keating, M.J., McCredie, K.B., Bodey, G.P., Smith, T.L., Gehan, E., Freireich, E.J. JAMA (1982) [Pubmed]
  10. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., Saxena, K. Mol. Cell (2004) [Pubmed]
  11. Tumor necrosis factor alpha stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factor. Hoang, T., Levy, B., Onetto, N., Haman, A., Rodriguez-Cimadevilla, J.C. J. Exp. Med. (1989) [Pubmed]
  12. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response. Burke, P.J., Karp, J.E., Vaughan, W.P. J. Natl. Cancer Inst. (1981) [Pubmed]
  13. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. Douer, D., Koeffler, H.P. J. Clin. Invest. (1982) [Pubmed]
  14. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. Buick, R.N., Messner, H.A., Till, J.E., McCulloch, E.A. J. Natl. Cancer Inst. (1979) [Pubmed]
  15. Lithium reinduction of acute myeloblastic leukemia. Orr, L.E., McKernan, J.F. Lancet (1979) [Pubmed]
  16. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. Ladanyi, M., Samaniego, F., Reuter, V.E., Motzer, R.J., Jhanwar, S.C., Bosl, G.J., Chaganti, R.S. J. Natl. Cancer Inst. (1990) [Pubmed]
  17. Isolation and analysis of the 21q+ chromosome in the acute myelogenous leukemia 8;21 translocation: evidence that c-mos is not translocated. Drabkin, H.A., Diaz, M., Bradley, C.M., Le Beau, M.M., Rowley, J.D., Patterson, D. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  18. The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFalpha2 transcription factor. McNeil, S., Zeng, C., Harrington, K.S., Hiebert, S., Lian, J.B., Stein, J.L., van Wijnen, A.J., Stein, G.S. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  19. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Janssen, J.W., Steenvoorden, A.C., Lyons, J., Anger, B., Böhlke, J.U., Bos, J.L., Seliger, H., Bartram, C.R. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  20. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Konopleva, M., Tsao, T., Ruvolo, P., Stiouf, I., Estrov, Z., Leysath, C.E., Zhao, S., Harris, D., Chang, S., Jackson, C.E., Munsell, M., Suh, N., Gribble, G., Honda, T., May, W.S., Sporn, M.B., Andreeff, M. Blood (2002) [Pubmed]
  21. p120 GAP requirement in normal and malignant human hematopoiesis. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M., Szczylik, C., Zon, G., Arlinghaus, R.B., Gewirtz, A., Perussia, B., Calabretta, B. J. Exp. Med. (1993) [Pubmed]
  22. Activation of an N-ras gene in acute myeloblastic leukemia through somatic mutation in the first exon. Gambke, C., Hall, A., Moroni, C. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  23. Sensitivity to 5-azacytidine of blast progenitors in acute myeloblastic leukemia. Wang, C., McCulloch, E.A. Blood (1987) [Pubmed]
  24. CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Dunussi-Joannopoulos, K., Krenger, W., Weinstein, H.J., Ferrara, J.L., Croop, J.M. Blood (1997) [Pubmed]
  25. The mitogenic response to tumor necrosis factor alpha requires c-Jun/AP-1. Brach, M.A., Gruss, H.J., Sott, C., Herrmann, F. Mol. Cell. Biol. (1993) [Pubmed]
  26. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Cuenco, G.M., Nucifora, G., Ren, R. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  27. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Rambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A.R., Dinarello, C.A., Cozzolino, F. Blood (1991) [Pubmed]
  28. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34- blasts from acute myelogenous leukemia. Akashi, K., Harada, M., Shibuya, T., Eto, T., Takamatsu, Y., Teshima, T., Niho, Y. Blood (1991) [Pubmed]
  29. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Lensch, M.W., Tischkowitz, M., Christianson, T.A., Reifsteck, C.A., Speckhart, S.A., Jakobs, P.M., O'Dwyer, M.E., Olson, S.B., Le Beau, M.M., Hodgson, S.V., Mathew, C.G., Larson, R.A., Bagby, G.C. Blood (2003) [Pubmed]
  30. Intensive chemotherapy for acute myelogenous leukemia. Gale, R.P., Foon, K.A., Cline, M.J., Zighelboim, J. Ann. Intern. Med. (1981) [Pubmed]
  31. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Igarashi, T., Wynberg, J., Srinivasan, R., Becknell, B., McCoy, J.P., Takahashi, Y., Suffredini, D.A., Linehan, W.M., Caligiuri, M.A., Childs, R.W. Blood (2004) [Pubmed]
  32. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Phillips, G.L., Reece, D.E., Shepherd, J.D., Barnett, M.J., Brown, R.A., Frei-Lahr, D.A., Klingemann, H.G., Bolwell, B.J., Spinelli, J.J., Herzig, R.H. Blood (1991) [Pubmed]
  33. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Advani, R., Saba, H.I., Tallman, M.S., Rowe, J.M., Wiernik, P.H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman, M., Sikic, B.I., Greenberg, P.L. Blood (1999) [Pubmed]
  34. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blaise, D., Maraninchi, D., Michallet, M., Reiffers, J., Jouet, J.P., Milpied, N., Devergie, A., Attal, M., Sotto, J.J., Kuentz, M., Ifrah, N., Dauriac, C., Bordigoni, P., Gratecos, N., Guilhot, F., Guyotat, D., Gluckman, E., Vernant, J.P. Blood (2001) [Pubmed]
WikiGenes - Universities